Variable name;level;Overall;Yes;No;p;test
;n;1351;266;1085;;
Age;[0 -30);95;63 (66.3);32 (33.7);<0.001;
;[30 -35);247;121 (49);126 (51);;
;[35 -40);457;78 (17.1);379 (82.9);;
;40+;550;4 (0.7);546 (99.3);;
Age (mean);;38.7 [34.9, 41.6];32.8 [30.0, 35.5];40.0 [36.8, 42.0];<0.001;nonnorm
Number of children;0;374;181 (48.4);193 (51.6);<0.001;
;1;276;53 (19.2);223 (80.8);;
;More than 1;701;32 (4.6);669 (95.4);;
BMI;<18.5;78;16 (20.5);62 (79.5);0.034;
;18.5-24.9;809;185 (22.9);624 (77.1);;
;25-29.9;254;47 (18.5);207 (81.5);;
;>=30;106;12 (11.3);94 (88.7);;
BMI (mean);;22.6 [20.4, 25.4];22.0 [20.3, 24.4];22.7 [20.6, 25.7];0.006;nonnorm
Treatment center;Curie Paris;813;171 (21);642 (79);0.150;
;Curie St Cloud;537;95 (17.7);442 (82.3);;
Genetic analysis;No;651;56 (8.6);595 (91.4);<0.001;
;Yes;700;210 (30);490 (70);;
Hereditary predisposition;No;543;159 (29.3);384 (70.7);0.346;
;Yes;142;48 (33.8);94 (66.2);;
Inflammatory BC;No;1332;264 (19.8);1068 (80.2);0.532;
;Yes;18;2 (11.1);16 (88.9);;
Clinical Tumor size (mm);;30.2 (21.5);31.7 (20.1);29.8 (21.8);0.206;
Clinical T stage (TNM);T0-T1;588;101 (17.2);487 (82.8);0.035;
;T2;589;135 (22.9);454 (77.1);;
;T3-T4;165;29 (17.6);136 (82.4);;
Clinical N stage (TNM);N0;853;169 (19.8);684 (80.2);0.993;
;N1-N2-N3;489;96 (19.6);393 (80.4);;
SBR grade;Grade I;58;11 (19);47 (81);0.615;
;Grade II;524;97 (18.5);427 (81.5);;
;Grade III;758;157 (20.7);601 (79.3);;
BC subtype;Luminal;703;121 (17.2);582 (82.8);0.032;
;TNBC;242;55 (22.7);187 (77.3);;
;HER2+/HR+;195;50 (25.6);145 (74.4);;
;HER2+/HR-;81;14 (17.3);67 (82.7);;
Histological type;NST;1259;252 (20);1007 (80);0.284;
;Lobular;53;6 (11.3);47 (88.7);;
;Others;37;8 (21.6);29 (78.4);;
Neoajuvant chemotherapy;No;740;120 (16.2);620 (83.8);0.001;
;Yes;610;146 (23.9);464 (76.1);;
Chemotherapy setting;Adjuvant;740;120 (16.2);620 (83.8);<0.001;
;NAC;609;146 (24);463 (76);;
Fertility preservation discussion;No;900;3 (0.3);897 (99.7);<0.001;
;Yes;450;263 (58.4);187 (41.6);;
